echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Beyond vaccines, what are the means scientists are developing to deal with the new crown outbreak?

    Beyond vaccines, what are the means scientists are developing to deal with the new crown outbreak?

    • Last Update: 2020-08-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Last week, the COVID-19 Emergency Committee, recruited by the Director-General of the World Health Organization, held its fourth meeting and, after full discussion and review of the evidence, agreed that the COVID-19 outbreak remained a public health emergency of international concern and that the COVID-19 pandemic was expected to continue for a long time.
    the Committee's series of recommendations to the World Health Organization (WHO) and States parties, accelerating research and promoting access to diagnostic tools, treatments and vaccines is one of the important recommendations.
    since the outbreak of COVID-19, the development of a new coronary virus vaccine has been under way at an unprecedented rate, and several vaccines are currently being developed into Phase 3 clinical trials.
    However, even if clinical trials prove that vaccines are safe and effective, we still need treatments for COVID-19, testing, and public health measures to control the further development of the epidemic and save patients' lives before they can protect the world's people.
    , let's take a look at the latest developments in biopharmaceutical companies outside of vaccines.
    to improve immunity in vulnerable populations, Lilly Launched Phase 3 Preventive Research in Antibodies Lilly and Company today announced the launch of Phase 3 clinical trial BLAZE-2.
    evaluate the effectiveness of the new coronary virus and antibody LY-CoV555 in the new crown virus developed jointly with AbCellera to prevent new crown virus infection and COVID-19.
    the clinical trial will be conducted in nursing homes across the United States, including elderly and health care workers in nursing homes.
    that for older people, the immune response triggered by the new crown vaccine may be weaker, and this population is one of the most vulnerable in the new crown outbreak.
    therefore, the development of other means to enhance the immunity of the elderly is an important part of controlling the new crown outbreak and saving the lives of patients.
    LY-CoV555 is a medium antibody developed jointly by Lilly and AbCellera.
    because antibodies have a longer half-life in the body, after a infusion, they can remain in the body for weeks or even months to provide passive immunity to people who receive injections.
    this is especially important for people (immune system defects or the elderly) who may not be able to develop effective immune protection through vaccination.
    This is a unique clinical study, and Lilly, in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), can provide on-site infusion services and the goods and services needed for clinical trials in nursing homes across the country by transforming RVs (RVs) and trailers into mobile clinical trial sites.
    The trial will register high-risk residents and staff in nursing homes with recent COVID-19 cases, assess whether one dose of LY-CoV555 reduced the rate of new coronary virus infection within four weeks, and whether one dose reduced COVID-19-related complications within eight weeks.
    expected to recruit up to 2,400 participants.
    "COVID-19" has had a devastating effect on nursing home residents.
    are developing drugs as soon as possible to stop the virus from spreading to these vulnerable individuals.
    While clinical trials are not easy in this situation, we are meeting the challenge of helping those who need us most," said Dr. Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Labs.
    " Takeda, AbbVie, and Amgen conducted adaptive platform trials to test a variety of COVID-19 therapies Today, AbbVie, Amgen, and Takeda, members of the COVID Research and Development Alliance, announced that the first patient was enrolled in the Adaptive Platform Trial called I-SPY COVID.
    This clinical trial will evaluate the efficacy of CCR2/CCR5 dual antagonist cenicriviroc, PDE4 inhibitor Otezla (apremilast), and the antidynamic peptide B2 receptor Firazyr (icatibant) in patients who require high-flow oxygen therapy.
    these treatments are based on their potential impact on the immune system response of patients who need breathing support for COVID-19.
    About 10-15% of COVID-19 patients develop acute respiratory distress syndrome (ARDS), and 60% of patients entering the ICU require an average of two weeks of breathable support, with it estimated that half of them will not survive.
    Otezla may inhibit inflammation caused by immune response; Firazyr may improve pulmonary edema driven by hydroplytic peptides; and cenicriviroc may help reduce the severity of ARDS in patients with severe COVID-19 by blocking the transport of monocytes to tissues.
    the study is the product of a collaboration between members of the COVID Research and Development Alliance and Quantum Leap Healthcare, as well as the FDA.
    it uses Quantum Leap's adaptive platform trial design to improve the efficiency of clinical trials by minimizing the number of people involved in clinical trials and evaluating the time required for potential therapies.
    "Hospital patients can't wait long, we urgently need treatment options, and I'm proud to join AbbVie, Amgen, and others in the COVID research and development alliance and launch key platform trials like I-SPY," said Dr. Andy Plump, co-founder of the COVID Research and Development Alliance and president of Takeda Research and Development.
    , together with experts from different companies and industries, is expected to accelerate promising clinical trials of therapies under study and early discovery of treatments that will be effective for this serious disease.
    " NIH's selection of seven innovative new crown tests to invest nearly $250 million in expanded production come after the National Institutes of Health (NIH) announced that its Rapid Acceleration diagnostics project has invested a total of nearly $250 million in seven biomedical diagnostic companies to support the further development and expansion of COVID-19 testing based on laboratory or bedside testing.
    RADx process diagram (Photo: Credit, NIH) RADx project was launched on April 29 this year to rapidly develop testing methods for COVID-19.
    received more than 650 applications for the project, and after multiple rounds of evaluation by hundreds of experts, RADx selected seven companies for testing to expand production and plans to launch it through RADx.
    tests have not yet been approved by the FDA.
    biotech companies that have reached this milestone include Point-of-Care Tests Mesa Biotech, and San Diego-based Accula SARS-CoV-2, which uses handheld RT-PCR devices and compact disposable test boxes to detect viral RNA at the point of care.
    can read the results from the removable test card in 30 minutes.
    Quidel, San Diego Quidel Sofia SARS Antigen FIA Kit is a side-flow immunoassay that, together with Sofia and Sofia2 analyzers, is used for bedside testing, such as in a doctor's office or pharmacy.
    there are now thousands of Quidel analyzers in the United States, and the U.S. Department of Health and Human Services (HHS) has determined that the technology could be used in nursing homes.
    analyzer gives electronic results within 15 minutes.
    Talis Biomedical, menlopak Talk One COVID-19 bedside test is a multi-test kit for use with portable Talk One instruments.
    detection detects the new crown virus through the iso-temperature amplification and optical detection system of viral RNA, returning the results within 30 minutes.
    laboratory testing of Ginkgo Bioworks, Boston's Ginkgo Bioworks uses automated and high-volume next-generation sequencing technology to test samples on a large scale, processing tens of thousands of tests simultaneously.
    Ginkgo Bioworks will work with schools, public or private companies and local patient groups to provide end-to-end sample collection and report results within 24-48 hours.
    helix, San Mateo Helix will deliver standardized kits for bulk collection of nasal swabs to public health departments, health care systems and other customers.
    can collect tens of thousands of samples at a time and process them within 24-48 hours.
    a combination of complex automated processes and next-generation sequencing techniques, Helix expects to process up to 50,000 samples per day by the end of September 2020 and 100,000 samples per day by the end of the year.
    Fluidigm, each BioMark HD microflow platform in South San Francisco has the ability to handle thousands of new crown virus PCR tests every day, mainly using saliva samples.
    has many Fluidigm instruments in clinical and research laboratories across the United States that will provide tens to hundreds of thousands of new tests per day by fall 2020 by expanding the deployment of its advanced integrated microflow chips.
    Mammoth Biosciences, THES-CoV-2 DETECTR testing in Mammoth Biosciences, South San Francisco, uses CRISPR technology, which provides simpler workflows and faster turnaround times than traditional laboratory PCR testing.
    this high-volume solution can increase the detection capability of commercial laboratories many times. Dr Bruce J. Tromberg, director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), said,
    These new technologies, emerging from the testing and RADX pipeline, will not only guide patient care and control public health measures for virus transmission, but will also give us better weapons for dealing with future pathogens and diseases."
    " References: s1, Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Institute of Diseases (NIAID). Retrieved August 3, 2020, from Members of the COVID R and D Alliance Quantum and Leap Healthcare Collaborative First Patients in I-SPY COVID Trial. Retrieved August 3, 2020, from NIH delivering new COVID-19 testing technologies to meet U.S. demand. Retrieved August 3, 2020, from ▽ attention to the Public No.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.